Molecular You has announced the successful close of a $5 million USD Series A financing, led by Voloridge Health, with additional support from Dynamic Leap and others.
This investment marks a pivotal step in scaling their predictive health platform, which utilizes cutting-edge molecular medicine to advance preventative healthcare.
With just a single blood sample, Molecular You’s platform analyzes over 250 biomarkers spanning all major biological systems. This enables the identification of health risks at their root cause, offering a thorough snapshot of an individual’s health across 25 different areas. The platform translates this information into highly personalized, actionable lifestyle recommendations, empowering users to take preventative measures before symptoms develop. This approach stands in contrast to traditional diagnostics, which usually occur after symptoms appear and require multiple blood tests for individual detection.
Recent achievements for Molecular You include nationwide launches in Canada and the United States, both in clinical settings and direct-to-consumer channels. The company has also partnered with HealthQuest Esoterics to run its assay as a Lab Developed Test (LDT), making it eligible for reimbursement. Looking ahead, Molecular You plans to release a next-generation multi-omic assay capable of measuring over 800 biomarkers, significantly expanding its analytical power and the scope of conditions it can address, including select cancers.
Molecular You’s technology has already shown promise, as seen in the detection of stage 1 pancreatic cancer in an asymptomatic 60-year-old woman, enabling early intervention and a positive outcome. The company’s progress comes amid a surge in investment in the longevity sector, which more than doubled between 2023 and 2024, reaching $8.5 billion according to a recent report from Longevity Technology.
How the funding wil be used: This funding will help Molecular You further expand its platform, customer base, and impact within both consumer and clinical markets.
KEY QUOTES:
“We plan to use this capital to grow our customer base across both consumer and clinical channels in North America, while also continuing to expand the platform’s analysis and predictive capabilities.”
Jim Kean, CEO of Molecular You, who has decades of expertise pioneering within the health testing space, including previously founding WellnessFX and building the technology underlying WebMD’s consumer platform
“We’re bringing scientific discipline and clinical-grade rigor to the booming consumer wellness sector and delivering brand new tools to enhance what clinical practices can provide. Fragmented measurement of individual biomarkers cannot offer the same predictive capabilities as our platform, which sees the body as a whole. This is critical for predictive and preventative medicine, particularly for complex conditions like Alzheimer’s, PCOS, and autoimmune diseases, which are correlated to multiple individual biomarkers that are typically measured separately.”
Dr. Murdoc Khaleghi, Chief Medical Officer at Molecular You
“Molecular You is advancing a critical shift in healthcare, from reactive treatment to predictive and preventive care, through biomarker science and real-world clinical impact. Their unique multi-omic platform integrates proteomics and metabolomics in a way that sets a new standard for precision health. This aligns with our mission to leverage data science for better health outcomes, and we believe Molecular You is well-positioned to transform how individuals and providers detect and manage disease risk at scale.”
David Vogel, CEO of Voloridge Health
